Invivyd (IVVD) Cash from Operations (2021 - 2025)
Invivyd posted quarterly Cash from Operations of 15455000.0 for Q4 2025, up 58.91% year-on-year from 9725801.89 in Q4 2024, and down 87.33% on a QoQ basis from 8250000.0 in Q3 2025.
Invivyd (IVVD) has 5 years of Cash from Operations data on file, last reported at 15455000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 58.91% year-over-year to 15455000.0; the trailing twelve-month figure through Dec 2025 stood at 58135000.0 (up 65.9% YoY), and the FY2025 full-year result was 58135000.0, up 65.9% from the prior year.
- Cash from Operations for Q4 2025 stood at 15455000.0, down from 8250000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 8250000.0 in Q3 2025 and bottomed at 73212000.0 in Q4 2021.
- The 5-year median for Cash from Operations is 41124500.0 (2023), against an average of 40325650.0.
- The widest annual swing landed in 2022, when Cash from Operations slumped 148.72%; it then surged 79.91% in 2025.
- A 5-year view of Cash from Operations shows it stood at 73212000.0 in 2021, then jumped by 35.25% to 47404000.0 in 2022, then decreased by 24.97% to 59240000.0 in 2023, then surged by 36.51% to 37610000.0 in 2024, then surged by 58.91% to 15455000.0 in 2025.
- The last three Cash from Operations figures came in at 15455000.0 (Q4 2025), 8250000.0 (Q3 2025), and 13301000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -15.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.46 Mn |
| Dec 31, 2025 | -15.46 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -21.13 Mn |
| Mar 31, 2025 | -21.13 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Sep 30, 2024 | -41.07 Mn |
| Sep 30, 2024 | -41.07 Mn |
| Jun 30, 2024 | -41.60 Mn |
| Jun 30, 2024 | -41.60 Mn |
| Mar 31, 2024 | -50.21 Mn |
| Mar 31, 2024 | -50.21 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Jun 30, 2023 | -37.39 Mn |
| Jun 30, 2023 | -37.39 Mn |
| Mar 31, 2023 | -41.18 Mn |
| Mar 31, 2023 | -41.18 Mn |
| Dec 31, 2022 | -47.40 Mn |
| Dec 31, 2022 | -47.40 Mn |
| Sep 30, 2022 | -56.14 Mn |
| Sep 30, 2022 | -56.14 Mn |
| Jun 30, 2022 | -57.39 Mn |
| Jun 30, 2022 | -57.39 Mn |
| Mar 31, 2022 | -59.05 Mn |
| Mar 31, 2022 | -59.05 Mn |
| Dec 31, 2021 | -73.21 Mn |
| Dec 31, 2021 | -73.21 Mn |
| Sep 30, 2021 | -54.21 Mn |
| Sep 30, 2021 | -54.21 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Mar 31, 2021 | -23.74 Mn |
| Mar 31, 2021 | -23.74 Mn |